The once-daily pill, icotrokinra, was tested in patients with moderate-to-severe plaque psoriasis, a skin condition that ...
In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds of ...
Psoriasis is an inflammatory disease, so it stands to reason that vitamin D may have something to do with either the development or course of the condition. Research shows that vitamin D levels ...
A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback